PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8922732-17	1996	However, SB 209670 potently antagonized coronary artery contractions induced by endothelin-1 with a pA2 of 8.84 +/- 0.32.	Antimony	9-11	endothelin 1	Homo sapiens	80-92	
9605569-18	1998	SB 209670 (0.1 and 1 microM) virtually abolished responses to ET-1 in the human pulmonary resistance artery.	Antimony	0-2	endothelin 1	Homo sapiens	62-66	
10340912-10	1999	CONCLUSION: The pharmacokinetics of intravenous SB 209670 appeared to be linear, and infusion resulted in dose-related increases in immunoreactive endothelin-1.	Antimony	48-50	endothelin 1	Homo sapiens	147-159	
9918747-2	1998	Here, we have compared the influence of the novel mixed ETA/ETB antagonists SB/217242, SB/234551 and SB/209670 on ET-1-mediated vasoconstriction in these vessels.	Antimony	76-78	endothelin 1	Homo sapiens	114-118	
9918747-2	1998	Here, we have compared the influence of the novel mixed ETA/ETB antagonists SB/217242, SB/234551 and SB/209670 on ET-1-mediated vasoconstriction in these vessels.	Antimony	87-89	endothelin 1	Homo sapiens	114-118	
8058755-2	1994	SB 209670, which was rationally designed using conformational models of ET-1, selectively inhibits binding of 125I-labeled ET-1 to cloned human ET receptor subtypes ETA and ETB (Ki = 0.2 and 18 nM, respectively).	Antimony	0-2	endothelin 1	Homo sapiens	72-76	
7881741-2	1995	The aim of the present study was to assess the ability of SB 209670, a high affinity non-peptide endothelin receptor antagonist (0.4 and 18 nM Kis at human cloned ETA and ETB receptors, respectively), to inhibit the haemodynamic actions of endothelin-1 in vivo.	Antimony	58-60	endothelin 1	Homo sapiens	240-252	
8058755-2	1994	SB 209670, which was rationally designed using conformational models of ET-1, selectively inhibits binding of 125I-labeled ET-1 to cloned human ET receptor subtypes ETA and ETB (Ki = 0.2 and 18 nM, respectively).	Antimony	0-2	endothelin 1	Homo sapiens	123-127